NEW YORK, Feb. 11, 2016 /PRNewswire/ -- This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 393 pages. The personalized medicine (global & USA) market is presented as follows:
- By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)- By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies)- By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) - By Therapy (Cancer, Cardiovascular, Infectious Disease)
Key Opinion Leaders that contributed to interview questions within the report include:- Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group- Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland- Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC- Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland- Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine- Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine- David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine- Deborah Phippard, PhD, Vice President, Research, Precision for Medicine- Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for MedicineA wealth of financial data & business strategy information is provided including:- Company financials, sales & revenue figures- Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies- Business Model Strategies for Providers. Provider Systems and Academic Medical Centres- Business Model Strategies for Payers & Governments- Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property- How to Gain Market Penetration in the EU- Cost-effectiveness and Business Value of Personalized Medicine- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)- Comprehensive account of company product portfolios & kits
SWOT, Economic & Regulatory Environment specifics include:- Key strengths, weaknesses and threats influencing leading player position within the market- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)- Top fastest growing market segments and emerging opportunities- Top pharmaceutical companies within the IPM by market share and revenue- Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)- CE-marked Personalized Medicine/Diagnostic Tests- FDA Advances in Personalized Medicine RegulationThis report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.- 23andMe- Abbott Laboratories- Abbott Molecular Inc.- Admera Health (GENEWIZ)- Affymetrix - Agendia- Alere- Amgen- Astex Pharmaceuticals- AstraZeneca- Atossa Genetics- Becton Dickenson- bioMerieux- BristolMyersSquibb- Cancer Genetics- Celera (Quest Diagnostics) - Celldex Therapeutics - Claritas Genomics- CuraGen- Danaher (Leica Biosystems)- deCode Genetics (Amgen)- Foundation Medicine - EDP Biotech- Eli Lilly- ELDA BioTech- Eisai- Genelex- GlaxoSmithKline- Human Longevity Inc (Cypher Genomics)- HalioDx- Ikonisys- Illumina- InterGenetics- Johnson & Johnson- LabCorp- Life Technologies- Merck- MDxHealth- MolecularMD Corporation- Monogram Biosciences- Myriad - Nodality- Novartis MDx- Orion Genomics- Oxford BioTherapeutics- NanoString Technologies- Pfizer- Qiagen- Roche Molecular Diagnostics- Sanofi- SensiGen- Siemens Healthcare Diagnostics- Takeda- Thermo Fisher Scientific- Transgenomic- Ventana (Roche)- Vermillion (Ciphergen)- Vertex PharmaceuticalsWhat you will gain:- An in-depth understanding of the global personalized medicine market and it's environment- Current market facts, figures and product lines of key players in the industry- Emerging trends in key markets such as the US, UK, Germany and France- Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing- Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies- FDA approved pharmacogenetic tests and recognized biomarkers- Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry
This report tackles key concerns to the personalized medicine market such as:- Lack of regulatory policy and legislation in the US and Europe- Reimbursement schemes and payers concerns- Transition of investigational diagnostic assays and therapeutics to clinical practice- Direct to consumer (DTC) test kits and implications for the publicWho should read this report?- Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine- Industry professionals and business strategists will discover key information to propel their policies- Investors will gain inside information to dominant players in the industry and future forecasts- Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environmentThis report will tell you if the companies mentioned are:- Strong, competitive players- Pooling their resources for specific growth and therapeutic areas- Investing strategically in R&D- Have a history of strategic M&A activityThis detailed report is supported with 360 figures and tables over 393 pages and profiles the main pharmacos in personalized medicine.Benefits of Investing in our Cutting-Edge Reports:Clients receive complementary content* with mid-level and enterprise wide licencesPost-sale complementary consultation with senior expert analyst is includedUse of tables and figures in your own reports and presentations is permittedEach report provides straight-talking strategic analysis & sector intelligenceAll reports are updated each quarter to give you the most up-to-date information
* Subject to terms & conditions negotiated with Kelly Scientific Publications prior to saleRead the full report: http://www.reportlinker.com/p03118741-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
Advertisement
- By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)- By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies)- By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) - By Therapy (Cancer, Cardiovascular, Infectious Disease)
Advertisement
Key Opinion Leaders that contributed to interview questions within the report include:- Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group- Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland- Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC- Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland- Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine- Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine- David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine- Deborah Phippard, PhD, Vice President, Research, Precision for Medicine- Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for MedicineA wealth of financial data & business strategy information is provided including:- Company financials, sales & revenue figures- Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies- Business Model Strategies for Providers. Provider Systems and Academic Medical Centres- Business Model Strategies for Payers & Governments- Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property- How to Gain Market Penetration in the EU- Cost-effectiveness and Business Value of Personalized Medicine- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)- Comprehensive account of company product portfolios & kits
SWOT, Economic & Regulatory Environment specifics include:- Key strengths, weaknesses and threats influencing leading player position within the market- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)- Top fastest growing market segments and emerging opportunities- Top pharmaceutical companies within the IPM by market share and revenue- Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)- CE-marked Personalized Medicine/Diagnostic Tests- FDA Advances in Personalized Medicine RegulationThis report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.- 23andMe- Abbott Laboratories- Abbott Molecular Inc.- Admera Health (GENEWIZ)- Affymetrix - Agendia- Alere- Amgen- Astex Pharmaceuticals- AstraZeneca- Atossa Genetics- Becton Dickenson- bioMerieux- BristolMyersSquibb- Cancer Genetics- Celera (Quest Diagnostics) - Celldex Therapeutics - Claritas Genomics- CuraGen- Danaher (Leica Biosystems)- deCode Genetics (Amgen)- Foundation Medicine - EDP Biotech- Eli Lilly- ELDA BioTech- Eisai- Genelex- GlaxoSmithKline- Human Longevity Inc (Cypher Genomics)- HalioDx- Ikonisys- Illumina- InterGenetics- Johnson & Johnson- LabCorp- Life Technologies- Merck- MDxHealth- MolecularMD Corporation- Monogram Biosciences- Myriad - Nodality- Novartis MDx- Orion Genomics- Oxford BioTherapeutics- NanoString Technologies- Pfizer- Qiagen- Roche Molecular Diagnostics- Sanofi- SensiGen- Siemens Healthcare Diagnostics- Takeda- Thermo Fisher Scientific- Transgenomic- Ventana (Roche)- Vermillion (Ciphergen)- Vertex PharmaceuticalsWhat you will gain:- An in-depth understanding of the global personalized medicine market and it's environment- Current market facts, figures and product lines of key players in the industry- Emerging trends in key markets such as the US, UK, Germany and France- Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing- Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies- FDA approved pharmacogenetic tests and recognized biomarkers- Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry
This report tackles key concerns to the personalized medicine market such as:- Lack of regulatory policy and legislation in the US and Europe- Reimbursement schemes and payers concerns- Transition of investigational diagnostic assays and therapeutics to clinical practice- Direct to consumer (DTC) test kits and implications for the publicWho should read this report?- Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine- Industry professionals and business strategists will discover key information to propel their policies- Investors will gain inside information to dominant players in the industry and future forecasts- Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environmentThis report will tell you if the companies mentioned are:- Strong, competitive players- Pooling their resources for specific growth and therapeutic areas- Investing strategically in R&D- Have a history of strategic M&A activityThis detailed report is supported with 360 figures and tables over 393 pages and profiles the main pharmacos in personalized medicine.Benefits of Investing in our Cutting-Edge Reports:Clients receive complementary content* with mid-level and enterprise wide licencesPost-sale complementary consultation with senior expert analyst is includedUse of tables and figures in your own reports and presentations is permittedEach report provides straight-talking strategic analysis & sector intelligenceAll reports are updated each quarter to give you the most up-to-date information
* Subject to terms & conditions negotiated with Kelly Scientific Publications prior to saleRead the full report: http://www.reportlinker.com/p03118741-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-to-2019--strategic-analysis-of-industry-trends-technologies-participants-and-environment-300219237.html
SOURCE Reportlinker
